Q2 2022 Enovis Corp Earnings Call
Ladies and gentlemen, thank you for standing by and welcome to the Endeavour second quarter 2022 earnings call. All lines have been placed on mute to prevent any background noise.
After the Speakers' remarks, there will be a question and answer session.
He would like to ask a question during this time.
Press Star then the number one on your telephone keypad to withdraw your question simply press Star one again.
I would now like to turn the call over to Derek Let go. Please go ahead Sir.
Thank you Paul Good morning, everyone. Thank you for joining us today for our second quarter results conference call and Derek lockout, Vice President of Investor Relations. Joining me on the call today are Matt <unk>, our CEO , Chris <unk> Executive Vice President and CFO and also joining US. This morning for a quick introduction before we get to the prepared remarks and Q&A is been Barry.
We previously announced will serve as <unk> CFO and Chris retires at the end of the year.
Our earnings release was issued earlier this morning and is available in the investors section of our website <unk> Dot com.
I'll be using a slide presentation to walk you through today's call, which can also be found on our website.
The audio and slide presentation of this call will be archived on the website later today and will be available until the next quarterly conference call.
During this call, we'll be making some forward looking statements about our beliefs estimates regarding future events and results.
These forward looking statements are subject to risks and uncertainties, including those set forth in the safe Harbor language in today's earnings release, and our filings with the SEC.
Actual results may differ materially from any forward looking statements that we make today.
We're looking statements speak only as of today, and we do not assume any obligation or intent to update them, except as required by law.
With respect to any non-GAAP financial measures referenced during the call today. The accompanying reconciliation information relating to those measures can be found in our press release and in the appendix of today's slide presentation.
You will note that we have provided reconciliation tables for each of the 2021 quarterly historical results on an adjusted Standalone basis for comparability.
With that let me turn it over to Matt for some opening remarks, and then we will start for the earnings presentation.
Thank you Derek about a month ago, we announced our planned trended transition for the <unk> CFO role, which will culminate in Chris's retirement at the end of the year and then taking on the role.
After his retirement and Chris will remain with us in an advisory capacity through 2023 to ensure a smooth transition.
Chris was one of my first hires after I joined the company as CEO back in 2015.
His leadership has been pivotal to our operating improvement and two our strategic transformation to a pure play Med Tech company. He also raise the bar for the global finance function and attracted great talent like Ben which strengthened the capabilities of the team.
He had been considering his retirement path for a while and I know that he is looking forward to spending more time with his family and friends and pursuing other passions.
Dan joined US in early 2020, as the CFO of our Med Tech segment. After many years of finance leadership experience in the sector. We've been impressed with how quickly. He has learned the business and immediately rose to the Covid challenges that emerged as he walked in the door.
Dan has made a meaningful impact to our operational performance and growth strategy in a short time and he's a strong leader with high integrity and I'm confident that he'll build on the strong foundation that Chris is established I look forward to working with Ben as we establish <unk>.
At a high performing Med Tech company.
You'll get to know band more in the coming quarters I've asked him to briefly introduce himself on this call Ben Thanks.
Thanks, Matt.
I'm really excited about the opportunity and the extremely bright future we have in front of us at <unk>.
My entire career in med tech space and prior to joining us.
Number.
Finance leadership roles at the AD environment.
I played a key role.
Val.
In 2019.
<unk>.
What attracted me.
The revenue growth potential.
And fast growth.
Expansion capabilities and a great Foundation.
The Atlas platform.
Being part of the organization over the last couple of years have only strengthened my view the significant growth opportunities we have in the company.
I really look forward to partnering with Chris during this transition and continuing to work with Matt Brady the rest.
Leadership teams to bill.
Sure.
Now.
Now I'll turn it back over to Matt who will start on slide three.
Thanks, Pat now, let's get into the Q2 discussion.
We've had strong growth and solid operating performance. So far this year executing in line with our plan.
We remain confident in achieving our strategic goals of sustainable high single digit organic revenue growth, 20% adjusted EBITDA margins and over $2 billion in annual sales in the coming years.
I want to take a moment here to acknowledge the foundation of our success our global team of talented associates.
The contributions in the first half of 2022.
June we had our first leadership conference as the Novus and <unk> face to face, it's great to be doing things a lot more face to face. These days. So it's incredible to see the energy and excitement we have that we have created through the launch.
Through the separation and the launch of <unk>.
Discuss growth plans.
We're applying our <unk> toolkit throughout the company and our purpose values and behaviors that shape, our continuous improvement culture.
I am incredibly proud of our team and confident in their ability to continue to build a fine fantastic growth company.
Turning to slide four.
We're achieving our operational goals in 2022 with double digit top line growth and organic growth in the solid mid single digits.
Our organic growth of just over 5% for the first half of the year has us on track for our 6% to 9% full year guide and clearly shows our capability to grow high single digit organic and more more normalized markets.
On this page you can see our second quarter highlights, including an 11% increase in sales.
Once again, both of our business segments outperformed their markets, leveraging our innovation and commercial muscle to gain share and providing reliable service to customers. Despite the supply chain challenges.
We also achieved 11% growth in EBITDA and we held the line on EBITDA margins, even with the unprecedented inflation and some lingering COVID-19 related market impact that just delayed surgeries and pressure on staff.
We added 30 basis points of margin improvement in the first half and still expect to have strong improvement for the full year. It is a solid step towards our 20% goal.
We completed two acquisitions in the quarter inside medical systems, and $3 60, Medicare and on slide five I want to highlight the <unk> technology that we acquired via insight.
Harvest.
Is a key element of our surgical enabling technologies ecosystem.
As part of our strategic focus on delivering measurably better outcomes.
We are focused on creating technology enabled workflows for surgeons that are tailored to their procedures and our end to their operating environment.
In shoulder our math point solution is used broadly by surgeons to digitally plan their surgery and create a three D printed patient specific instruments to enable greater efficiency and precision.
In hip and knee there is strong surgeon demand for guidance and positioning to drive repeatable outcomes and for the marketing benefits of having the newest technologies for patients.
Existing guidance and robotic platforms improve accuracy, but can be costly and consume quite a bit of time in the procedure and too much space in the operating theater.
Our strategic focus has been on delivering even higher accuracy and efficiency and a smaller footprint and at a lower cost.
We partnered with insight for the past three years to accelerate the development and commercialization of their breakthrough guidance technology.
With the acquisition of insight, we are launching our state of the art augmented reality surgical guidance solution Rvs with initial focus on hip and knee.
<unk> is a cutting edge easy to use technology that is highly precise and accessible at a lower cost and footprint than current assisted surgery offerings in the marketplace. The.
<unk> headset provides the surgeon with critical real time data, while leaving an unobstructed view set of surgeons never take their eyes off the patient.
With a single instrument set and no need for preoperative scan RF is a streamlined and efficient part of the overall surgical procedure.
The feedback from our first 200 cases has been fantastic with surgeons at the world's top institutions like the Mayo clinic already seeing great success using this technology.
Even more exciting the small lightweight self contained nature of harvest is a perfect solution for the high growth ASC segment.
<unk> is just the fuel our teams need to continue our strong share gain in knee and hip implants in the U S and also generate additional high margin revenue streams.
We also see potential for extension into extremities and for globalization.
Turning to slide six we summarize our 47% Recon segment growth that includes high single digit organic growth up against the tough comp.
This performance is well above market growth rates again, and includes 14% growth in U S hips, and knees and 8% growth in U S extremities with double digit growth in shoulder.
Our year to date organic growth overall in U S. Recon is 10%, which we believe is about three times the market.
Our mats business pro forma organic growth was about 10% in Q2, and we've only just begun to see the synergy benefits. We expect as we proceed through the second half.
As we commented last quarter, we're seeing some short term fluctuations at this stage of the Covid recovery, but we remain encouraged by the continued growth in elective surgery volumes around the world.
Yes.
Our prevention and recovery business also demonstrated attractive growth as shown on slide seven.
Our 4% sales per day growth was better than underlying markets and in line with our three year plan to create a consistent mid single digit grower in this segment.
And this quarter, we grew faster in international PNR market as U S growth moderated a bit due to a strong comp and some short term market pressure.
Our global <unk> business also grew mid single digits, and we have a strong pipeline of new product launches ahead, which will support solid mid teens vitality index.
Yes.
We saw additional supply chain and wage inflation in Q2, and PNR and are deploying additional price increases to offset it.
We remain confident in our ability to pull back the significant price cost compression. We saw in this business over the past few years as inflation stabilizes.
With that I'll turn the call over to Chris who will unpack our financial results a little further starting on slide eight Chris.
Hey, Thanks, Matt and thank you for the kind words earlier and band is great absolutely great to have use our future CFO I'm really excited for you in the future of the company with you.
The finance cheap for the business. Thank you.
We had another quarter of double digit sales growth in Q2, including strong contributions from our recent acquisitions year over year currency headwinds Steffen from one point last quarter to three points in the second quarter. As previously discussed we had about two points lower sales from fewer selling days and our Q2.
Per day growth of 5% was similar to Q1 and about in line with our expectations for the upcoming third quarter.
<unk> covered other sales details earlier, including the impact from Covid on procedures and staffing at our continued.
And outperformance versus the market.
Gross margins were down 40 basis points versus the prior year due to the higher levels of inflation that read through this quarter. As a reminder, the inflation pressures that started with COVID-19 had accumulated to about $30 million by the start of this year and we have realized about $10 million of pricing increases through our sale.
As channels.
This $20 billion of net pressure has further increased in the first half of this year, we continue to deploy pricing adjustments and we are seeing signs of inflation stabilization that should lead to margin relief as we get deeper into the second half of the year.
Our EBITDA grew in line with revenue and margins were consistent with our previous guidance. Despite inflationary pressures our existing businesses expanded margins by 70 basis points due to a combination of sales growth and structural cost reductions.
This margin expansion would have been greater except for the inflation and currency translation impacts.
As the U S dollar strengthened we incurred a $2 million currency translation reduction in our EBITDA in the second quarter.
In the second quarter, we also executed a tax planning project that created a one time benefit a reduced our Q2 adjusted rate down to 9%.
We are expecting the rate to be in the low to mid <unk> for the remainder of the year and in the low twenties for the full year.
Our Q2 adjusted EPS includes about <unk> <unk> from the currency translation impact and 10 cents of tax benefit you put these together and that would normalize to about 51.
Which is in line with expectations.
Overall, we delivered against our operating forecast for the quarter and dealt with some FX pressures.
Let's turn to slide nine and talk about our outlook for the full year and some of the key contributing factors.
Our organic growth range range remains unchanged at 6% to 9%, which allows for a range of outcomes related to the COVID-19 recovery pace, our current trajectory likely points us toward the middle of that range as.
As observed throughout the Med Tech space July was a slower month, but we are seeing signals of an acceleration into the remainder of the quarter and are confident of again, achieving mid single digit organic growth in Q3.
We continue to expect further acceleration in the fourth quarter in part due to easier comps.
As commented earlier, we are experiencing an increased level of currency translation pressures and have updated our full year outlook for this factor with another two to three points of pressure.
Overall reported growth is now expected to be 8% to 12%.
Acquisitions continue to be on track with earlier expectations.
Our currency impacts are affecting both the topline and profitability I mentioned that we took a $2 million hit to EBITDA in Q2, because of this and the full year impact is expected to be $10 million.
We have been successfully battling the challenges in our operating environment and feel that it's prudent to leave our operating forecast in place, but we are reducing our overall guidance by $10 million.
Lastly, as large currency impact.
So we're now targeting $235 million to $255 million of EBITDA in 2022.
Our full year EPS range is shifted a nickel to reflect the net effects from currency and the tax benefit discussed earlier.
For the third quarter, we expect sequentially lower revenue from Q2 to account for the slower July start and the vacation season and despite this we're expecting Q3 EBITDA margins to be in line with the second quarter due to increasing momentum of our cost and pricing actions.
Wrapping up on slide 10, we are pleased that our strategy for organic growth outperformance continues to clearly read through in our results.
Our businesses are well positioned in their markets with robust innovation pipelines and effective operations and serve our customers well, while managing through dynamic business conditions are.
Our operating execution is complemented by our proven M&A program and we continue to acquire the right businesses and technologies to further strengthen our growth profile.
And with that Paul.
It's going to open up the call for questions.
Hi.
Thank you the floor is now open for your questions to ask a question at this time. Please press star one on your telephone keypad at any point you would like to withdraw from the queue. Please press star one again.
Okay.
Your first question comes from the line of Jeff Johnson of Baird.
Yes.
Thank you. Good morning, guys can you hear me okay.
Yes, yes, Jeff Good morning, Jeff, Hey, Matt, Hey, Matt Hey, Chris Derek how are Ya alright. So just a couple of questions. Here I think you did a good job explaining kind of the pacing here that we should expect on organic growth over the next few quarters that we're going to be my first question, but let me shift instead I guess on <unk> I just wanted to understand you put up 8% selling day adjusted growth.
You did talk about 8%.
Extremities growth in the U S, 14% hip and knee hip.
Hip and knee 14, and U S extremities up a what couldnt get down into eight overall for <unk> I'm, assuming maybe that some of your own business thats been deemphasizing Mathis kind of scales up, but just kind of help us understand the differential there. Thanks.
Yes, yes, Jeff there are there are two things one there is a little bit of effect from the little bit of O U S business that we that we had that Youre correct is.
It has been.
And a couple of places that are under some pressure.
This is Ben.
Being migrated to.
From a map standpoint, but that's that.
Small effect the other thing is that in the U S.
Strong growth in hip and knee and shoulder.
In foot and ankle.
We're on a good path on that business, but as we've talked about before there's a couple of things a couple of things going on there we actually have very strong growth in our in our med <unk> business and in some of the key technologies in that business and overall the med shape in trillium businesses that we acquired or are growing at or above market rates.
<unk>.
But the star business, we've talked about before.
Is going through a period of.
Some work that we have to do to get the business on the right course in terms of some some regulatory work.
And so star is not contributing to growth in that business right now and we also in the first half of the year late last year in the first half of the year, we're working through a channel consolidation to create one aligned strong channel for our foot and ankle business and with that came some additions and subtractions in the channel, which resulted in a little bit.
Short term churn in the first half of the year, particularly in the second quarter and so foot and ankle is the single digits part of that.
Offsets all those other double digit parts and so that puts us very much on track to build this recon portfolio to be a consistent double digit performer at this larger scale based on the pieces that are already there and then the clear path, we have in foot and ankle, we expect to be well into the double digits in the back half of the year in foot and ankle. So we're feeling good about.
The path there.
Alright Thats helpful. Thank you and then maybe just two clarifying questions.
You pointed to some market pressure on the P&L side.
To think about PNR, often being driven by travel trauma that happens a car accident sports things like that and obviously the world is opening back up so what's the market pressure there and you said you've seen some signs of inflationary pressure stabilizing I think you'd be one of the first companies to knowledge that so any insight on stabilization there that youre seeing would be helpful.
Thanks.
Yes, sure. So first of all in terms of PNR market pressure in one piece of that business is driven off of.
Off of elective surgery.
And with a little bit of a delay there and so even some of the Q1 pressure there wasn't elective surgery flows into Q2 market pressure for us in that business and so that's.
Particularly in the U S.
There is a little bit of impact on that elective surgery part of that that business.
There are some parts of that business that are very clinic heavy and and also.
Served much older parts, our footwear business, there really focuses in on diabetics and more.
More age aging population and.
There was yes, there was some drops in in clinic visits through the through the second quarter as well in that business. So those are really the two sources of pressure in PNR, both of which as elective surgery continues to expand and as we get to the other side of Covid the ship fully clear.
From a second one is about inflation you you asked about stabilization of inflation, yes, if we go back.
Six to nine months.
We still would every month find about new inflation rate, we'd have the next the next supplier coming to us with an increase with all the reasons or or.
Another increase in freight rates or a fuel surcharge on free rates. So we were in a period, where things kind of kept going up and that even lasted and into the first quarter of the year.
We had expected some stabilization, but we continue to see some more increases coming through but but in the last three months.
Really there is a different.
Kind of different texture to that and we don't see that kind of weekend week out increases coming through we're seeing much more flattening of input prices.
And freight rates and.
In some cases, we've seen some small reductions like freight rates out of China spiked and then they've come down a little bit and in some cases, we're starting to get a little bit of a decrease maybe we source. The second supplier and now we are in a position with little little different market and a second supplier. We're in a position to start bringing things back down.
We're not calling it in terms of things coming back down and we certainly can't be certain that they wont go up again, but we do see stabilization that we expect should enable us to start to pull back a little bit of price cost in the back half year, particularly as we get to Q4, because we have one.
Quite a bit of freight through that business.
And have the opportunity to turn that into some margin reversal at the gross margin level.
Alright very helpful. Thank you.
Thanks, Jeff.
Your next question.
And on that.
Yeah.
Your next question comes from the line of Vik Chopra of Wells Fargo.
Hey, good morning, and thanks for taking the question two for me I just wanted to dig in a little bit deeper on the procedure volume trends that you saw can you talk about the impact that staffing shortages have had on procedure volumes across both DNR and recon and then I had a follow up thanks.
Yes sure Vic.
Volume trends again, I think it's.
It's been talked about a lot out there and I'll just give our version but certainly the.
The year started slow kind.
Kind of building off of the slow finish to last year.
As we kind of headed through and into March and even April there was really good momentum building, there and you heard very little about.
Cancellations in staffing shortage and things like that but then as we made our way through.
Through the second quarter late in the quarter kind of late May early June we started to hear here again about that.
About higher cancellation rates related usually to COVID-19 testing, sometimes to staffing issues and we also.
Have seen.
Isolated areas.
We call it staffing pressure, but in in.
In some cases, it's really.
Longer vacations, I think we've got some people that.
Whether it is surgeons are their staffs that.
I've been kind of not doing a whole lot of vacation in the last few years and I think in June and July .
We saw in some cases kind of more significant vacation downtime than we have in the past in those in those months and so those are some of the things that we've seen in may and the elective surgery is really speaking about the U S.
And but we also have gotten really really good signals about what what's expected to happen in August and September .
There is.
Kind of a better short term trend in terms of cancellations and scheduling is.
Seeing that there is going to be.
This trend through the cover it through the quarter in terms of people getting kind of back aggressively into a ramp up of elective surgery and then certainly there's plenty of pent up demand that people want to get out as we come down the stretch.
Of the year here.
On the PNR side again, we didn't get the secondary impact.
Those elective surgery trends on a part of that.
Business and then I think there has been a smaller effect that you do have some some staffing pressure on different different clinics out there that was probably a little bit of a factor in the market in the first couple of quarters of the year as well.
Thanks for that comprehensive answer of Super helpful. My follow up question was on M&A, you've closed a number of deals in the past couple of years to tuck in acquisitions this quarter as well, but just given the recent pullback in the market should we expect a larger deal from you guys or is the focus going to remain.
These tuck in M&A late stage technology deals. Thanks, so much.
Yeah. Thanks, Vik, yes, so I think.
We've been consistent.
Saying that.
The things kind of things we've done over the past few years are very representative of the kinds of things that we expect to do in the next couple of years we've done.
A set of.
Highly strategic deals.
In some cases bring great technologies that accelerate the growth of our business and our open up new applications and segments. In some cases, we brought new market landscape, whether it's geographic like the math is deal.
Or whether it's.
Getting into a new a new segment like for like the foot and ankle deals.
And so those have all been driven office strategy and they've made our company better they've created a higher organic growth profile, a higher gross margin profile opportunities to get synergies and scaling that drive us up the EBITDA margin curve and so that collection of things that you've seen us do over the past couple of years is very represent.
Dave of what we'd expect to do in the coming years and those were deals that range from deals with no revenue.
Two.
Two.
100, almost $150 million of revenue and so theres lots of possibilities for us over the next couple of years that would be similar to those.
We've obviously got great balance sheet room in order to do those.
Clearly there are also a little bit larger things that we can think about over time and will always be <unk>.
Considering those and how they could accelerate our strategy and move our company forward create a lot of value for our shareholders. We've got a great capability to do deals and integrate them integrate them well, but I'd still say in the short term expect to see more of the same because there is a lot of it in our pipeline, obviously, a little different climate in terms of.
Valuation and the opportunity there to maybe get a little more reasonable valuations than in the past and so we're really excited about the M&A opportunities in the next couple of years here.
Your next question comes from the line of Matthew Mitchell line of Keybanc.
Hey, good morning, and congratulations Chris.
In retirement.
I just wanted to start with with EBITDA.
Uh huh.
Down.
The revision.
10 million distinctly for FX, it's a way to think about it that you are seeing.
Incremental supply chain logistics inflation pressure, but euro what your.
Your ability to kind of offset those.
Keeping the range just to what what FX looks like given like organic growth seemingly coming again in line with what your expectations are.
Yes, Matt you Peel that apart pretty well I think there's two separate things that we're dealing with there is the inflation that we've had the supply chain challenges in the business that Matt spoke to in his and I guess I referred to a bit in my comments as well and what we've seen on that is that there is a pressure curve that was building all through since Cove.
<unk> initiated we started some pricing actions.
Sort of last year and into this year.
It's helped to ameliorate some of that but we've still been we still have that curve. That's on US now as we see the inflation stabilizing and these price increases are reading through better we expect that that that pressure in particular will continue to be contained to maybe moderate now.
There's a question there about exactly how that will play out, but if the stabilization that we see in the price increases that were working on are all realized we should get to a better a better position than we expect to get to a better position on margins. The separate issue is.
With respect to currency and that is something that we just don't have as much control over and we thought it was important.
To make sure that folks see that we're executing our operating plan.
In line with what we'd expected and there is that inflation pressure and the pricing dynamic that keeps us from moving up in our original guidance, but at the same time, we've got to deal with this and address the and recognize acknowledged the currency pressure thats coming through so the operating plan operating effectively our team I think our teams are doing a really good.
In a difficult environment.
But then we do have to adjust the guidance range for the currency impacts.
Yes, I think Thats fair.
Switching over to the M&A.
Ed.
I just want to make sure that.
The revenue expected from those two are immaterial to guidance for two.
2022.
And then on Rvs is it agnostic to different implants or is this a proprietary surgical platform for you or for you.
Douglas.
Yes, Matt let me take those in one thing I do want to put a point on in Chris's comments is that the $10 million of FX pressure is since we set guidance right. So.
We have $10 million of new FX pressure beyond our original guidance and that's why we are changing the range is just for the avoidance of doubt there.
So the revenues from the new acquisitions, yes, there'll be sort of just a handful of million dollars of impact in this year and so it's.
And on.
On the on the RV side, though there'll be some some costs coming in and so.
No no real profit contribution there in the year, but.
To your question about about harvest.
Well I will say, but certainly those will both grant ramp nicely as we move into next year and beyond both support the growth in existing parts of the business and also brings in additional revenue as well.
As far as our agenda today.
I think a terrific technology that we think is going to.
Obviously, there's an appetite for these kinds of.
<unk> technologies now that is very well established in the industry.
And <unk>.
<unk> is designed to be more precise but very importantly, also designed to be.
Much much smaller more streamline and particularly for the ASC environment, just a terrific fit and yes. It is it is an implant agnostic solution, but from a business model standpoint, we're certainly looking to use it to.
Serve our existing surgeons and help them in.
Grow grow in a strong way with them and also get some recurring revenue coming from from their use of this product.
And their processes, but then also we do definitely see as a great opportunity for us.
Yes.
It's part of how we continue to attract patented searches.
As we do that we will have a business model that certainly and encourages them. They're excited about the technology to be also bringing their implant volume over to us over time and also a great recurring revenue stream on the on the <unk> product as well.
Okay excellent forward to dental.
Thanks.
Okay.
Your next question comes from Jason with surplus capital.
Hi, Thanks for taking the questions first off you mentioned, you're implementing price increases I'm wondering where you think youre going to have success, you've got somewhat of a wide range of orthopedic products in different markets, such as hips and knees versus extremities and obviously the physical therapy business. So.
Could you give us some color in terms of where you think youre seeing success or where you think you can get sketch of where youre seeing success right now.
Yes, Jason So our PNR segment is.
Where we had the most inflation come the earliest and where we've we've done a lot of price and we continue to do to do more price and.
There's different pieces of that segment, but the bracing businesses is the largest part of that segment.
And there there is there is a range from Medicare made made price increases we're working through with the other insurers getting the getting increases that help our reimbursement business. There we've been able to several times now make direct price increases into the into the clinics and our distributors and then.
Some of the changes from Medicare and insurers create some some relief on that front and we've made some traction on GPO price increases.
And so it is it.
It is something we have to do channel by channel and sometimes customer by customer and so it has been building over time.
But thats in the bracing business, whereas like in our rehab business. That's something we can just put a price increase through because it is a product thats sold into into rehabilitation clinics and so we've had a couple a couple of price increases into our rehab business that are just <unk>.
The price lets get it through the system.
As well and so we had.
About in there in that $1 billion PNR platform, we had just about a percent of price already last year and we expect to have.
In the range of 2% of price this year in.
And that.
If we get to stabilization in our in our <unk> and our frame rate, that's what Chris talked about in the back half of the year gets us to start pulling back some gross margin, particularly in Q4, and then we would pull back more next year.
And that kind of a scenario and if we get more inflation. We do now have a lot of clear kind of muscle and process and experience to be able to get to the places where we can get it through and get it through.
On the recon side, it's a very different dynamic.
There definitely is a different price climate in recon.
And we have seen some specific instances here in the U S. In some specific countries in Europe .
Where we've been able to get some positive price.
But.
But there also has been a trend in that recon business that typically have a couple of percent of price down every year and I would say, there's definitely going to be a lot of price dialog in recon.
This year and next year. There was some last year I think most indications are that that's probably going to result in more of a.
A flattening or maybe a modest increase for a little bit of time, rather than that normal couple of percent a year end and our business with the high growth. We've got if we get flattening of price with nice operating leverage I think that'd be a good environment to be in say next year.
Got it. Thanks, that's very helpful. And then also in terms of your longer term EBITDA margin improvements I think you could.
Put a pretty decent go out there I think it's 500 basis points by 2024.
How does inflation and FX and all those other pressures work into that assumption.
Are those sort of pressures.
Pressures that may delay you getting to that level or was that a rebuilt in when you kind of put out those numbers or that expectation.
Yes, so we share that kind of a very clear plan for how we're going to get those 500 basis plant points and I think that plan is still fully intact I'm very confident we can get that improvement and get to 20% plus EBITDA margins I'm also confident that we will take.
A good healthy step forward on that here this year and that's because the key elements of it are still very much intact. We've taken out some of the structural costs as we did the separation and we've had some other cost actions underway.
This year and plans for next year.
We're getting the growth and the operating leverage and the productivity that we can get.
With that growth and we've got clear plans for how to scale those acquisitions that came in at low margin levels, but high gross margin levels and we've got clear plans for how is starting as we exit this year and into the coming years, how we scale those those acquisitions and so all of that's intact and we're getting price, we're getting a lot of price and so the <unk>.
Opportunity to eventually pull the price.
Cost.
Pressured back in our <unk> business is.
It is very real so I still feel very confident in that 500 500 basis point I think we've clearly got a short term challenge in terms of a little bit of delays in getting to stabilization on inflation and a little bit of FX pressure.
That's creating a little bit of headwind against that initial short start but the entire plan to get 500 basis points is still very secure.
Got it. Thank you that's very helpful. And then I guess, one sort of sort of housekeeping type question could you give us a little color in terms of what the hip and knee growth breakout was.
Any any kind of.
The qualitative.
Information in terms of what's driving that growth.
Yes, so we.
We shared the hip and knee that we shared.
On the page there is U S U S hip and knee because we don't yet have.
Matt This in our in our core numbers and as we shared we're kind of well into the well into the double digits. There certainly the.
The nice part of that.
<unk> is the strongest that we grow very strongly in knee.
Many times of market and Thats.
Partly driven by how successful we are being in the in the ASC with our tremendous empower knee.
Our tremendous empower any product, but but also enhance we are confident that we grew it at multiple times market, so well into the double digits for our hip and knee and as we said.
Digit says well for for shoulder.
And.
In our mats business.
Our hip growth they are a real leader in hip and knee or hip growth was very strong well above market.
We've shared previously that we expect that <unk> will bring in from the U S. Our <unk> product and our empower.
<unk> significantly improved their knee and shoulder growth and so we're feeling very good at mad about math as being 10% pro forma in the quarter on the back of strong <unk> growth and then we've got the products needed coming through to get the other the other parts are very strong so.
Really good good Ark in our recon business.
Very helpful. Thanks, I'll jump back in queue.
Okay.
At this time. This does conclude today's question and answer session for today's call I will now turn the floor back over to management for any additional or closing remarks.
Well. Thank you everyone. Thanks for joining us if you have any further questions. Please contact investor relations have a great day. Thanks, everybody.
Ladies and gentlemen, this does conclude today's call. Thank you for your participation you may now disconnect.
Okay.
[music].
Okay.
[music].